Published in Vaccine Weekly, February 22nd, 2006
Study 1: CpG oligodeoxynucleotides (ODN) are better than Resiquimod as vaccine adjuvants.
According to a report from Canada, "TLR ligands that mimic pathogen associated molecular pat terns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as imiquimod and resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODNs) that bind to TLR9."
"This study compared...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly